A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

NCT02624167 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Schizophrenia

Interventions

DRUG: NW-3509A
DRUG: Placebo

Sponsor

Newron Pharmaceuticals SPA